CTRI/2016/07/007117进行中（未招募）1 期
A RANDOMIZED, SINGLE CENTER, DOUBLE BLIND, TWO-PERIOD, CROSSOVER GLUCOSE CLAMP STUDY TO TEST BIOEQUIVALENCE BETWEEN TWO FORMULATIONS OF RECOMBINANT HUMAN INSULINS; WOSULIN R (200 IU) WITH WOSULIN R (100 IU) IN HEALTHY SUBJECTS. - W-WOS(R)-103
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 56
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Ba/be
入排标准
入选标准
- •1.Body Mass Index (BMI) between 18.0 and 27.0 kg/m2, (both
- •2.Subjects with normal results of 2 hours Oral Glucose Tolerance
- •Test (OGTT) performed at screening.
- •3. Considered generally healthy upon completion of medical
- •history, physical examination, X-ray chest (PA view), ECG, and
- •biochemical investigations.
排除标准
- •1. HbA1c values (at screening) more than 5.7%.
研究者
相似试验
已完成
不适用
BA-BE Study (Insulin Aspart Injection Bioequivalence study in healthy volunteers)CTRI/2022/01/039265Wockhardt Bio AG56
暂停
不适用
STUDY TO COMPARE PHARMACOKINETICS AND PHARMACODYNAMICS BETWEEN TWO RECOMBINANT HUMAN INSULIN ANALOGUES - WOCKHARDTâ??S INSULIN ASPART MIX 70/30 AND NOVOLOGï?? MIX 70/30, IN HEALTHY SUBJECTS.CTRI/2015/06/005901Wockhardt Ltd
招募中
不适用
Bioavailability and Bioequivalence study of Wosulin N ProductCTRI/2021/04/032915Wockhardt Bio AG
尚未招募
不适用
Bioavailability and Bioequivalence study of Wosulin 30/70 ProductCTRI/2021/05/033411Wockhardt Bio AG
进行中（未招募）
不适用
A SINGLE-CENTRE, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY TO ASSESS SAFETY AND EFFICACY OF COMBINATION THERAPY WITH VARDENAFIL 10 mg AND TAMSULOSIN 0,4 mg IN THE TREATMENT OF MEN WITH PERSISTENT IRRITATIVE URINARY SYMPTOMS - FI.LU.VAEUCTR2010-022138-10-ITAZIENDA OSPEDALIERA UNIVERSITARIA CAREGGI